Complement in skin diseases

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 20, Issue 1, 2011, Pages 3-11

  Kotnik, Vladimir ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Autoimmunity; Bullous dermatoses; Complement; Deficiency; Dermatologic diseases; Psoriasis

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BULLOUS PEMPHIGOID ANTIGEN 1; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C8; COMPLEMENT INHIBITOR; DESMOGLEIN 1; DESMOGLEIN 3; DESMOPLAKIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 1ALPHA; LECTIN; MANNAN BINDING LECTIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANGIONEUROTIC EDEMA; APH50 TEST; BASOPHIL DEGRANULATION; BULLOUS PEMPHIGOID; CELIAC DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEFICIENCY; COMPLEMENT HEMOLYSIS TEST; COMPLEMENT SYSTEM; CUTANEOUS VASCULITIS; DERMATITIS HERPETIFORMIS; DIAGNOSTIC PROCEDURE; DISCOID LUPUS ERYTHEMATOSUS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE DISORDER; FAMILIAL PARTIAL LIPODYSTROPHY; GENETIC POLYMORPHISM; HUMAN; IMMUNOFLUORESCENCE; LICHEN PLANUS; PATHOGENESIS; PEMPHIGOID GESTATIONIS; PEMPHIGUS VULGARIS; PORPHYRIA; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; RECURRENT INFECTION; REVIEW; SEROLOGY; SIGNAL TRANSDUCTION; SKIN DISEASE; SKIN INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA; VASCULITIS; VIRUS DETECTION; XERODERMA PIGMENTOSUM;

COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; HUMANS; SKIN DISEASES;

EID: 80054899522     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Blaney DJ. Serum complement in dermatologic disease. South Med J. 1962;55:883-7.
2. Herrmann WP. [Current immunological developments in dermatology]. Hautarzt. 1969;20(1):293-6.
3. Morgan B. Complement and dermatological disease. In: Morgan B, editor. Complement clinical aspects and relevance to disease. London: Academic Press Limited; 1990. p. 156-78.
4. Jordon RE, Day NK, Sams WM, Jr., Good RA. The complement system in bullous pemphigoid. I. Complement and component levels in sera and blister fluids. J Clin Invest. 1973;52(5):1207-14.
5. Kirschfink M. [Disorders of the complement system: clinical aspects and diagnosis]. Dtsch Med Wochenschr. 1994;119(9):307-10.
6. Bos JD, Pasch MC, Asghar SS. Defensins and complement systems from the perspective of skin immunity and autoimmunity. Clin Dermatol. 2001;19(5):563-72. (Pubitemid 32927172)
7. Wong MM, Giudice GJ, Fairley JA. Autoimmunity in bullous pemphigoid. G Ital Dermatol Venereol. 2009;144(4):411-21.
8. Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol. 2005;14(12):861-75. (Pubitemid 41723203)
9. Feliciani C, Toto P, Amerio P. In vitro C3 mRNA expression in pemphigus vulgaris: complement activation is increased by IL-1alpha and TNF-alpha. J Cutan Med Surg. 1999;3(3):140-4. (Pubitemid 29056108)
10. Xu LY, Esparza EM, Anadkat MJ, Crone KG, Brasington RD. Cutaneous manifestations of vasculitis. Semin Arthritis Rheum. 2009;38(5):348-60.
11. Kulthanan K, Cheepsomsong M, Jiamton S. Urticarial vasculitis: etiologies and clinical course. Asian Pac J Allergy Immunol. 2009;27(2-3):95-102.
12. Tappeiner G. Immunodeficiency and complement deficiency states. Curr Probl Dermatol. 1989;18:116-9.
13. Ichikawa E, Furuta J, Kawachi Y, Imakado S, Otsuka F. Hereditary complement (C9) deficiency associated with dermatomyositis. Br J Dermatol. 2001;144(5):1080-3. (Pubitemid 34203367)
14. Grumach AS, Leitao MF, Arruk VG, Kirschfink M, Condino-Neto A. Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family. Clin Exp Immunol. 2006;143(2):297-304.
15. Speth C, Wurzner R, Stoiber H, Dierich MP. The complement system: pathophysiology and clinical relevance. Wien Klin Wochenschr. 1999;111(10):378-91. (Pubitemid 29258506)
16. Fleming CJ, Holme ER, Mackie RM. Systemic complement activation in psoriasis vulgaris. Clin Exp Dermatol. 1996;21(6):415-8. (Pubitemid 27198664)
17. Heimbach L, Li N, Diaz A, Liu Z. Experimental animal models of bullous pemphigoid. G Ital Dermatol Venereol. 2009;144(4):423-31.
18. Lapiere JC, Guitart J, Ettlin DA, Chen DM, Amagai M, Chan LS. Preferential activation of the complement system in the lower epidermis of patients with pemphigus vulgaris. Br J Dermatol. 1998;139(5):851-4.
19. DeAmicis T, Mofid MZ, Cohen B, Nousari HC. Hypocomplementemic urticarial vasculitis: report of a 12-year-old girl with systemic lupus erythematosus. J Am Acad Dermatol. 2002;47(5 Suppl):S273-4. (Pubitemid 35231837)
20. Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA, et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest. 1997;100(5):1256-63. (Pubitemid 27386312)
21. Lessey E, Li N, Diaz L, Liu Z. Complement and cutaneous autoimmune blistering diseases. Immunol Res. 2008;41(3):223-32.
22. Mao X, Sano Y, Park J, Payne A. MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris. J Biol Chem. 2011;286(2):38.
23. Kawana S, Geoghegan WD, Jordon RE, Nishiyama S. Deposition of the membrane attack complex of complement in pemphigus vulgaris and pemphigus foliaceus skin. J Invest Dermatol. 1989;92(4):588-92. (Pubitemid 19122114)
24. Namazi MR, Fallahzadeh MK, Shaghelani H, Kamali-Sarvestani E. Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol. 2010;49(2):146-8.
25. Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest. 2000;105(1):113-23. (Pubitemid 30036393)
26. Zhao M, Trimbeger ME, Li N, Diaz LA, Shapiro SD, Liu Z. Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol. 2006;177(5):3398-405. (Pubitemid 44277860)
27. Schmidt E, Bastian B, Dummer R, Tony HP, Brocker EB, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res. 1996;288(7):353-7. (Pubitemid 26232085)
28. Cianchini G, Masini C, Lupi F, Corona R, De Pita O, Puddu P. Severe persistent pemphigoid gestationis: long-term remission with rituximab. Br J Dermatol. 2007;157(2):388-9. (Pubitemid 47083837)
29. Cobo MF, Santi CG, Maruta CW, Aoki V. Pemphigoid gestationis: clinical and laboratory evaluation. Clinics (Sao Paulo). 2009;64(11):1043-7.
30. Semkova K, Black M. Pemphigoid gestationis: current insights into pathogenesis and treatment. Eur J Obstet Gynecol Reprod Biol. 2009;145(2):138-44.
31. Shornick JK, Artlett CM, Jenkins RE, Briggs DC, Welsh KI, Garvey MP, et al. Complement polymorphism in herpes gestationis: association with C4 null allele. J Am Acad Dermatol. 1993;29(4):545-9. (Pubitemid 23289553)
32. Mohammed I, Holborow EJ, Fry L, Thompson BR, Hoffbrand AV, Stewart JS. Multiple immune complexes and hypocomplementaemia in dermatitis herpetiformis and coeliac disease. Lancet. 1976;1(7984):487-90.
33. Preisz K, Sardy M, Horvath A, Karpati S. Immunoglobulin, complement and epidermal transglutaminase deposition in the cutaneous vessels in dermatitis herpetiformis. J Eur Acad Dermatol Venereol. 2005;19(1):74-9. (Pubitemid 40268144)
34. Gigli I, Schothorst AA, Soter NA, Pathak MA. Erythropoietic protoporphyria. Photoactivation of the complement system. J Clin Invest. 1980;66(3):517-22. (Pubitemid 10053916)
35. Stapelberg MP, Williams RB, Byrne SN, Halliday GM. The alternative complement pathway seems to be a UVA sensor that leads to systemic immunosuppression. J Invest Dermatol. 2009;129(11):2694-701.
36. Greaves MW, Tan KT. Chronic urticaria: recent advances. Clin Rev Allergy Immunol. 2007;33(1-2):134-43. (Pubitemid 351514146)
37. Zamiri M, Jury CS, Dawe RS, O'Neill S, Douglas WS. Reactivity to autologous serum skin test and relationship with complement levels in chronic idiopathic urticaria and angio-oedema. Clin Exp Dermatol. 2009;34(5):587-90.
38. Marsland AM. Autoimmunity and complement in the pathogenesis of chronic urticaria. Curr Allergy Asthma Rep. 2006;6(4):265-9. (Pubitemid 44056821)
39. Ono H, Kawaguchi H, Ishii N, Nakajima H. A point mutation in exon 7 of the Cl-inhibitor gene causing type I hereditary angioedema. Hum Genet. 1996;98(4):452-3. (Pubitemid 126745940)
40. Lipscombe TK, Orton DI, Bird AG, Wilkinson JD. Acquired Cl-esterase inhibitor deficiency: three case reports and commentary on the syndrome. Australas J Dermatol. 1996;37(3):145-8. (Pubitemid 126443071)
41. Bork K. Hereditary angioedema with normal Cl inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am. 2006;26(4):709-24. (Pubitemid 44666307)
42. Aydogan K, Karadogan SK, Adim SB, Tunali S. Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus. Int J Dermatol. 2006;45(9):1057-61. (Pubitemid 44317119)
43. Stone NM, Williams A, Wilkinson JD, Bird G. Systemic lupus erythematosus with Clq deficiency. Br J Dermatol. 2000;142(3):521-4. (Pubitemid 30159080)
44. Schwartz R. Complement Receptor Deficiency. 2010 [cited 2011 Mar 1]. Available from: http://emedicine.medscape.com/article/1051238-overview
45. Sun A, Wu YC, Liang LC, Kwan HW. Serum immunoglobulins, complements and circulating immune complexes in oral lichen planus. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1986;19(1):46-51. (Pubitemid 16080282)
46. Giraldo G, Degos L, Beth E, Sasportes M, Marcelli A, Gharbi R, et al. C8 deficiency in a family with xeroderma pigmentosum. Lack of linkage to the HLA region. Clin Immunol Immunopathol. 1977;8(3):377-84. (Pubitemid 8220767)
47. Orihara T, Tsuchiya K, Yamasaki S, Furuya T. Selective Clq deficiency in a patient with systemic lupus erythematosus. Br J Dermatol. 1987;117(2):247-54. (Pubitemid 17128478)
48. Hunziker T, Mollnes TE, Misiano G, Spath PJ. Complement in chronic cutaneous lupus erythematosus. Br J Dermatol. 1988;118(1):131-3.
49. Markey AC, MacDonald DM. Systemic lupus erythematosus with complement deficiency and IgA anticardiolipin antibody. Br J Dermatol. 1988;119(5):633-7.
50. Ochonisky S, Intrator L, Wechsler J, Revuz J, Bagot M. Acquired Cl inhibitor deficiency revealing systemic lupus erythematosus. Dermatol. 1993;186(4):261-3. (Pubitemid 23154543)
51. Darling M, Price ML. Cl inhibitor deficiency. Clin Exp Dermatol. 2005;30(6):725-6.
52. Burrows NP, Walport MJ, Hammond AH, Davey N, Jones RR. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol. 1991;125(1):62-7.
53. Liu CC, Kao AH, Hawkins DM, Manzi S, Sattar A, Wilson N, et al. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transi Sci. 2009;2(4):300-8.
54. Manzi S, Navratil JS, Ruffing MJ, Liu CC, Danchenko N, Nilson SE, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3596-604. (Pubitemid 39488685)
55. Tausk F, Harpster E, Gigli I. The expression of C3b receptors in the differentiation of discoid lupus erythematosus and systemic lupus erythematosus. Arthritis Rheum. 1990;33(6):888-92. (Pubitemid 20205771)
56. van Greevenbroek MM. The expanding role of complement in adipose tissue metabolism and lipoprotein function. Curr Opin Lipidol. 2009;20(4):353-4.
57. Lenane P, Murphy G. Partial lipodystrophy and renal disease. Clin Exp Dermatol. 2000;25(8):605-7. (Pubitemid 32105481)
58. Terui T, Ishii K, Ozawa M, Tabata N, Kato T, Tagami H. C3 production of cultured human epidermal keratinocytes is enhanced by IFNgamma and TNFalpha through different pathways. J Invest Dermatol. 1997;108(1):62-7. (Pubitemid 27019846)
59. Kansky A, editor. [Skin diseases and sexually-transmitted diseases]. Ljubljana: Zdruzenje slovenskih dermatovenerologov; 2002. Slovenian.
60. Timar KK, Junnikkala S, Dallos A, Jarva H, Bhuiyan ZA, Meri S, et al. Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol. 2007;44(11):2943-9. (Pubitemid 46412488)
61. Timar KK, Dallos A, Kiss M, Husz S, Bos JD, Asghar SS. Expression of terminal complement components by human keratinocytes. Mol Immunol. 2007;44(10):2578-86. (Pubitemid 46240326)
62. Carter CR, Whitcomb JP, Campbell JA, Mukbel RM, McDowell MA. Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB/c mice. Infect Immun. 2009;77(12):5668-75.
63. Lee WI, Kuo ML, Huang JL, Lin SJ, Wu CJ. Distribution and clinical aspects of primary immunodeficiencies in a Taiwan pediatric tertiary hospital during a 20-year period. J Clin Immunol. 2005;25(2):162-73.
64. Kotnik V, Kirschfink M. [How to recognize disturbances in complement system function.] Zdrav Vestn. 1995;64(6):335-43.
65. Funayama H, Huang L, Sato T, Ohtaki Y, Asada Y, Yokochi T, et al. Pharmacological characterization of anaphylaxis-like shock responses induced in mice by mannan and lipopolysaccharide. Int Immunopharmacol. 2009;9(13-14):1518- 24.
66. Tokodai K, Goto M, Imura T, Ogawa N, Fujimori K, Kurokawa Y, et al. C5a inhibitory peptide combined with gabexate mesilate is a clinically available candidate for preventing the instant blood-mediated inflammatory reaction. Transplant Proc. 2009;41(1):67-8.
67. Sanganee HJ, Baxter A, Barber S, Brown AJ, Grice D, Hunt F, et al. Discovery of small molecule human C5a receptor antagonists. Bioorg Med Chem Lett. 2009;19(4):1143-7.
68. Short A, Wong A, Finch A, Haaima G, Shiels I, Fairlie D, et al. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol. 1999;126(3):551-4. (Pubitemid 29087828)
69. Kohl J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr Opin Mol Ther. 2006;8(6):529-38. (Pubitemid 44921809)
70. Fleisig AJ, Verrier ED. Pexelizumab: a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass. Expert Opin Biol Ther. 2005;5(6):833-9. (Pubitemid 40873891)
71. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs. 2002;3(7):1017-23.